Stock Watch
The formation of the European Life Sciences Coalition by venture capital firms reflects investor strain rather than renewed confidence in European biotech. The outcome for syndicates of companies and investors has not always been good.
The separation of Merck’s human health business into oncology and non-oncology divisions could have been because the former will be a wasting asset after biosimilar erosion. There may also be other reasons.
Geopolitical events overshadowed Bayer’s financial results announcement, as was also the case for its peers. But Bayer’s history of acquisition and slow portfolio rejuvenation compound the clouds over its investment proposition.
Despite disease outbreaks highlighting the importance of prevention, antivax sentiment and political headwinds have brought significant challenges to the vaccine industry, while competitive dynamics are adding pricing pressure.
AstraZeneca’s fourth quarter leaned heavily on oncology as other segments lagged and margins missed expectations. It took CSL’s far weaker results put AstraZeneca’s solid, if unexceptional, performance into clearer perspective.
Global pharmaceutical operations can feel like a marathon slog as products launch in an environment of competitive and political pressures. Pfizer illustrated that overpaying for the wrong acquisition without proper due diligence may impede that hard-fought operational progress.
Roche’s decision to increase the dividend served to bolster its stock performance after revenue growth from a basket of patent-expired products exceeded key growth drivers like Vabysmo and full-year 2026 revenue guidance underwhelmed.
Despite group sales growth and its pharmaceutical division revenue weathering a big loss of exclusivity, J&J experienced stock price weakness after its fourth-quarter results announcement as geopolitical tensions depressed stock markets again.
Broad stock market tensions pervaded the atmosphere as the world’s premier healthcare conference got underway.A lack of big-ticket acquisition announcements and continuing drug pricing pressures did nothing to improve stock and index performances.
Often, what companies do not say is more important that what they do. Big headline reasons for falling sales might hide other less palatable and recurring attributions.
A bolus of year-end biotech acquisitions added to the strong performance of the sector in 2025. This activity may attract generalist investors back to the sector, but they should exercise caution.
Investor optimism can mask real risks; Biohaven’s setbacks show the need for objectivity and caution in pharma investing.
Regeneron epitomized best biotech practice by licensing its multi-blockbuster drugs to big pharma partners. Commercial success and the limitations of exclusivity have brought tensions to these relationships.
An investment only becomes appealing when all the ducks are in a row; if just one duck strays, investors can sense trouble and may hesitate before proceeding.
Pair trade strategies – using the stocks of two companies competing against each other with similar products – can be applied to pharmaceutical companies. Better still, where a winner and loser are correctly anticipated, a directional bias can increase profits.
AstraZeneca reported healthy results for the third quarter and its share price went up. Bayer reported poor results and its share price went up even more.
As the tide keeps receding on Pfizer’s pandemic product revenues, their replacement was to come from acquisitions. Seagen and Metsera have shown that execution and overpaying are key risks.
Reduced immunization rates in the US marred the results of both GSK and Merck, but with Merck’s biggest drug approaching its loss of exclusivity, lower vaccine sales and sluggish new product revenues spooked investors. GSK left more room for optimism.
Stock reactions to Sanofi’s and Novartis’s third-quarter results differed and involved a number of moving parts, including weak influenza vaccine sales at Sanofi. Both results were dominated by sales of their biggest drugs.
With third-quarter sales down year-on-year and quarter-on-quarter, Roche instead emphasized its performance over the first nine months of 2025, leading on the cumulative foreign exchange impact in the year to date to explain softer sales growth.